Menu
Search
|

Menu

Close
X

MediciNova Inc MNOV.OQ (NASDAQ Stock Exchange Global Market)

8.61 USD
-- (--)
As of Jun 22
chart
Previous Close 8.61
Open --
Volume --
3m Avg Volume 63,952
Today’s High --
Today’s Low --
52 Week High 14.50
52 Week Low 4.40
Shares Outstanding (mil) 41.13
Market Capitalization (mil) 38,720.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.116
FY17
-0.319
FY16
-0.334
FY15
-0.151
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
--
8.17
Price to Book (MRQ)
vs sector
4.56
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.55
LT Debt to Equity (MRQ)
vs sector
0.00
13.12
Return on Investment (TTM)
vs sector
-22.29
13.10
Return on Equity (TTM)
vs sector
-23.43
15.09

EXECUTIVE LEADERSHIP

Jeffrey Himawan
Independent Chairman of the Board, Since 2007
Salary: --
Bonus: --
Yuichi Iwaki
President, Chief Executive Officer, Director, Since 2014
Salary: $504,758.00
Bonus: $252,379.00
Carla Reyes
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Geoffrey O'Brien
Vice President, Since 2013
Salary: --
Bonus: --
Masatsune Okajima
Vice President, Head - Japanese Office, Since 2006
Salary: $293,550.00
Bonus: $102,743.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4275 Executive Sq Ste 650
LA JOLLA   CA   92037-1477

Phone: +1858.3731500

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.

SPONSORED STORIES